[Therapy of Parkinson's disease. Practical criteria of treatment].
D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001545:Benserazide / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D003533:Cyproheptadine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010891:Piribedil / Q000627:therapeutic use; D010918:Pizotyline / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use
D000978:Antiparkinson Agents; D006634:Histamine H1 Antagonists; D010276:Parasympatholytics; D010918:Pizotyline; D003533:Cyproheptadine; D007980:Levodopa; D001545:Benserazide; D011433:Propranolol; D000547:Amantadine; D010891:Piribedil; D002230:Carbidopa
La terapia del morbo di Parkinson. Criteri pratici di trattamento